Lieber mal ´ne XOMA, als vom MediaMarkt die Oma !


Seite 12 von 12
Neuester Beitrag: 12.08.11 15:01
Eröffnet am:16.03.04 20:44von: baanbruchAnzahl Beiträge:285
Neuester Beitrag:12.08.11 15:01von: CosmicTradeLeser gesamt:46.933
Forum:Hot-Stocks Leser heute:12
Bewertet mit:
3


 
Seite: < 1 | ... | 6 | 7 | 8 | 9 | 10 | 11 |
>  

5662 Postings, 6114 Tage _bbb_SERVIER announces Joint Development ...

 
  
    #276
05.01.11 14:57
XOMA / SERVIER announces Joint Development and Commercialization with XOMA on Novel Therapeutics for Orphan Disease
release date: 04/01/2011

http://www.servier.com/Corporate/NewsView.aspx?idx=1818  

3956 Postings, 5545 Tage dr.soldberg....

 
  
    #277
05.01.11 15:39

 http://collegestock.com/blog/622-stock-upgrades-amazon-com-inc-qcom-wag-xoma-veco/

 

die überschlagen sich alle mit den kurszielen;)

888 Postings, 5209 Tage and1loveitXOMA Infoseite

 
  
    #278
08.01.11 16:09

805 Postings, 6113 Tage KostolanyFANFRAGE

 
  
    #279
08.01.11 16:51
was meint ihr verdient xoma in 2011haben die in 2010 auch schon einen Umsatz erzeilt?, was denkt ihr könnte ein langfristiges Ziel für Jahresgewinne sein, gibt es Porgnosen???  

5275 Postings, 5032 Tage GropiusXoma, es geht scheinbar wieder los.

 
  
    #280
18.02.11 16:07
Handelsvolumen in der ersten halben Stunde höher als die sonstigen Tagesumsätze.  

1320 Postings, 5207 Tage xnomisXOMA Trial fails, i am feeling sorry

 
  
    #281
23.03.11 08:34
XOMA 052 Phase 2b Top Line Results: Glucose Control Not Demonstrated, Positive Anti-inflammatory Effect, Cardiovascular Biomarke
Xoma (NASDAQ:XOMA)
Intraday Stock Chart

Today : Wednesday 23 March 2011
Click Here for more Xoma Charts.

XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, today announced that its Phase 2b trial of XOMA 052 in Type 2 diabetes patients did not achieve the primary endpoint of reduction in glycosylated hemoglobin, or HbA1c, after six monthly treatments with XOMA 052 compared to placebo. Biological activity of XOMA 052 supporting its potential in cardiovascular disease was observed with highly significant (p <  or = 0.0005) decreases in C-reactive protein, or CRP, a biomarker for the risk of heart attack, stroke and other cardiovascular diseases, in all dose groups versus placebo. In addition, statistically significant (p<0.05) improvements in high-density lipoprotein, or "good" cholesterol were observed in two of four XOMA 052 dose groups versus placebo. XOMA 052 was well-tolerated in this trial, with no serious drug-related adverse events and a safety profile consistent with previous trials. XOMA is developing XOMA 052 in collaboration with Servier.

"While this trial did not demonstrate glycemic improvement, the potent anti-inflammatory effects and continued positive safety profile reinforce our Phase 3 development program for Behcet's uveitis, which we anticipate starting this year pending completion of regulatory agency discussions. We are also encouraged by the improvements in C-reactive protein and 'good' cholesterol, which support the further evaluation of XOMA 052 in cardiovascular disease and other inflammatory indications," said Steven B. Engle, XOMA's Chairman and Chief Executive Officer.

"Pending completion of the ongoing Phase 2a trial and analyses of both studies, we will be working with XOMA to determine the next steps in the XOMA 052 diabetes program. In parallel, we anticipate initiating the Phase 3 program in Behcet's uveitis this year. We also expect to take XOMA 052 into clinical development in cardiovascular disease in 2012," said Isabelle Tupinon-Mathieu, M.D., Head of Therapeutic Research and Development, Servier.

Phase 2b Trial Top Line Results

The randomized, placebo-controlled dose-ranging Phase 2b trial enrolled 421 patients at multiple sites in the United States during 2010. Eligible patients had Type 2 diabetes and were receiving metformin monotherapy, the standard of care for initial treatment of diabetes. Patients were randomized to receive one of four XOMA 052 doses or placebo monthly over six months via subcutaneous administration. The primary endpoint of the study was the change in HbA1c levels from baseline compared to placebo at six months.

Baseline characteristics were similar between the XOMA 052 and placebo groups. At study entry, the mean CRP was 4.8 mg/L and 4.2 mg/L in the XOMA 052 and placebo groups, respectively. Mean HbA1c was 7.8% for the XOMA 052-treated patients and 7.7% for placebo-treated patients. Mean duration of Type 2 diabetes was approximately six years in both groups.

At six months, all XOMA 052 doses had reductions in CRP, with adjusted mean percent changes from baseline that were highly significant compared to placebo with p-values (adjusted for multiple comparisons) at 0.0005 or less. Consistent with prior XOMA 052 studies, the median reductions in this trial were 33% to 54% in the four dose groups, compared with zero reduction for placebo.

In addition, despite the fact that more than half of the patients were receiving lipid-lowering medication, XOMA 052-treated patients demonstrated statistically significant increases in high-density lipoprotein, or "good" cholesterol, in two of the four XOMA 052 dose groups versus placebo (p<0.05).

The safety and tolerability profile in this population was consistent with previous XOMA 052 clinical trials, and there were no serious drug-related adverse events. The most common adverse events were upper respiratory infections with no differences between XOMA 052 and placebo groups. There were no reported opportunistic infections.  

4348 Postings, 4994 Tage koelnerschwabe...

 
  
    #282
23.03.11 13:27
++ Mittwoch, 23. März 2011, 13:00 Uhr ++
Bei XOMA Ltd. (WKN: 871239) könnten sich heute  exzellente Tradingchancen ergeben. Der Aktienkurs des US-Pharmaunternehmens ist nach einer schlechten News von über 5 US-Dollar nachbörslich bis auf etwa 3 US-Dollar gefallen. Entsprechend werden die Aktien derzeit in Deutschland gehandelt. Die News rechtfertigt in unseren Augen keinen derartig hohen Abschlag. Wir vermuten einen hohen Kursdruck zum Handelsstart in den USA, bevor eine starke Erholung erfolgen könnte. Intraday-Gewinne im Bereich von 15-25% erscheinen uns gut möglich. Bei der Hirsch AG hat sich die Lage unserer Ansicht nach nicht verändert. Wir bleiben sehr optimistisch, weisen aber nach wie vor ausdrücklich auf das Risiko eines Investments hin!  

2074 Postings, 6217 Tage Joschi307xoma 2,15 €

 
  
    #283
29.03.11 12:14
back to the roots..  

2074 Postings, 6217 Tage Joschi307Xoma 1,98 €

 
  
    #284
05.04.11 11:56
bodenbildung setzt langsam ein..  

1398 Postings, 6359 Tage CosmicTradeXOMA LTD. scheint niemanden zu interessieren?

 
  
    #285
12.08.11 15:01
Inzwischen auf 1,00 €  -60 % unter Allzeittief von 1,609 € gefallen (03.11.2010).

USA 1 Tag

Seite: < 1 | ... | 6 | 7 | 8 | 9 | 10 | 11 |
>  
   Antwort einfügen - nach oben